Loading...

Admedus

ASX:AHZ
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AHZ
ASX
A$35M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Admedus has significant price volatility in the past 3 months.
AHZ Share Price and Events
7 Day Returns
0%
ASX:AHZ
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-82.9%
ASX:AHZ
-3.3%
AU Medical Equipment
4.9%
AU Market
AHZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Admedus (AHZ) 0% 46.3% 50% -82.9% -86% -95.2%
AU Medical Equipment 4.1% -0.5% 1.1% -3.3% 38.7% 103.7%
AU Market -0% 1% 6.3% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • AHZ underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • AHZ underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
AHZ
Industry
5yr Volatility vs Market

Value

 Is Admedus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Admedus. This is due to cash flow or dividend data being unavailable. The share price is A$0.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Admedus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Admedus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:AHZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.08
ASX:AHZ Share Price ** ASX (2019-04-12) in AUD A$0.06
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Admedus.

ASX:AHZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:AHZ Share Price ÷ EPS (both in AUD)

= 0.06 ÷ -0.08

-0.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Admedus is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Admedus is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Admedus's expected growth come at a high price?
Raw Data
ASX:AHZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Admedus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Admedus's assets?
Raw Data
ASX:AHZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.04
ASX:AHZ Share Price * ASX (2019-04-12) in AUD A$0.06
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:AHZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:AHZ Share Price ÷ Book Value per Share (both in AUD)

= 0.06 ÷ 0.04

1.68x

* Primary Listing of Admedus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Admedus is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Admedus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Admedus has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Admedus expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Admedus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Admedus expected to grow at an attractive rate?
  • Unable to compare Admedus's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Admedus's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Admedus's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:AHZ Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:AHZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:AHZ Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ASX:AHZ Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 26 -22 -24
2017-12-31 23 -13 -17
2017-06-30 22 -12 -12
2017-03-31 21 -16 -15
2016-12-31 20 -20 -18
2016-09-30 17 -21 -21
2016-06-30 14 -22 -24
2016-03-31 13 -23 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Admedus is high growth as no earnings estimate data is available.
  • Unable to determine if Admedus is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:AHZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Admedus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:AHZ Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ASX:AHZ Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.08
2017-12-31 -0.07
2017-06-30 -0.05
2017-03-31 -0.06
2016-12-31 -0.08
2016-09-30 -0.10
2016-06-30 -0.13
2016-03-31 -0.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Admedus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Admedus's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Admedus's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Admedus's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Admedus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Admedus has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Admedus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Admedus's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Admedus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Admedus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Admedus's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Admedus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Admedus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:AHZ Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 25.60 -24.22 29.01 3.37
2017-12-31 22.61 -17.26 26.48 1.20
2017-06-30 22.32 -12.31 19.93 1.76
2017-03-31 21.07 -14.93 20.56 2.25
2016-12-31 19.82 -17.54 21.19 2.74
2016-09-30 16.99 -20.78 22.60 3.77
2016-06-30 14.15 -24.01 24.00 4.81
2016-03-31 13.03 -25.72 23.28 4.61
2015-12-31 11.91 -27.43 22.57 4.42
2015-09-30 11.02 -26.34 21.02 3.48
2015-06-30 10.13 -25.25 19.47 2.55
2015-03-31 9.39 -20.91 17.25 2.23
2014-12-31 8.65 -16.56 15.04 1.91
2014-09-30 8.30 -11.59 13.17 1.90
2014-06-30 7.94 -6.62 11.30 1.89
2014-03-31 7.84 -3.61 10.30 1.68
2013-12-31 7.75 -0.61 9.31 1.47
2013-09-30 7.58 -1.25 8.10 1.14
2013-06-30 7.42 -1.89 6.90 0.81
2013-03-31 7.15 -6.03 6.65 0.73
2012-12-31 6.89 -10.16 6.41 0.65
2012-09-30 6.68 -10.08 6.34 0.52
2012-06-30 6.46 -10.00 6.26 0.39

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Admedus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Admedus has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Admedus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Admedus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Admedus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Admedus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Admedus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Admedus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Admedus's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Admedus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Admedus has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Admedus Company Filings, last reported 3 months ago.

ASX:AHZ Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 21.48 0.00 12.04
2017-12-31 14.93 4.77 8.25
2017-06-30 23.97 0.00 11.26
2017-03-31 23.97 0.00 11.26
2016-12-31 29.92 0.00 14.34
2016-09-30 29.92 0.00 14.34
2016-06-30 22.64 0.00 8.81
2016-03-31 22.64 0.00 8.81
2015-12-31 32.55 0.00 19.15
2015-09-30 32.55 0.00 19.15
2015-06-30 38.56 0.00 24.03
2015-03-31 38.56 0.00 24.03
2014-12-31 26.31 0.00 9.60
2014-09-30 26.31 0.00 9.60
2014-06-30 37.17 0.00 19.58
2014-03-31 37.17 0.00 19.58
2013-12-31 24.50 0.00 9.31
2013-09-30 24.50 0.00 9.31
2013-06-30 16.47 0.00 2.45
2013-03-31 16.47 0.00 2.45
2012-12-31 9.91 0.00 1.99
2012-09-30 9.91 0.00 1.99
2012-06-30 10.43 0.02 2.06
  • Admedus has no debt.
  • Admedus had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Admedus has less than a year of cash runway based on current free cash flow.
  • Admedus has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.9% each year.
X
Financial health checks
We assess Admedus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Admedus has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Admedus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Admedus dividends.
If you bought A$2,000 of Admedus shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Admedus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Admedus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:AHZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:AHZ Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Admedus has not reported any payouts.
  • Unable to verify if Admedus's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Admedus's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Admedus has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Admedus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Admedus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Admedus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Admedus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Wayne Paterson
COMPENSATION A$1,232,760
AGE 51
TENURE AS CEO 2.1 years
CEO Bio

Mr. Wayne G. Paterson is the Founder and Chief Executive Officer of ProCom Rx since June 2013. Mr. Paterson has been Chief Executive Officer of Admedus Limited since March 15, 2017 and has been its Managing Director. He served as Interim Chief Executive Officer and Interim Managing Director of Admedus Limited from May 23, 2016 to March 15, 2017. Mr. Paterson served as Executive Vice President and Member of Management Board at Merck Serono S.A. From 2007 to 2013, he held senior positions at Merck Serono. He served as a Director at Cepheid since April 2015 until November 4, 2016. He served as Head of Emerging Markets including Russia, China, India and Brazil and Global Head Cardiovascular, Endochrine, Metabolic Medicine at Merck Serono S.A from June 2010 to December 2012. He also served as and President of Europe, Canada, Australia, Israel from December 2012 to June 2013. He was responsible for all aspects of company strategy, including manufacturing strategies, commercial operations and budgets. From January 2008 to June 2010, as President in Japan, Mr. Paterson created Merck Serono Japan and successfully managed all company divisions, launching several major products. He has extensive experience in the pharmaceutical industry, with specific expertise in APAC markets including China, Korea, Japan and Singapore including around 30 product launches. He served as Managing Director of Merck Serono Co. Ltd., Japan at Merck Serono S.A. Mr. Paterson joined Merck in 2005 as head of Oncology for Asia Pacific and was responsible for Merck Serono business in Japan as President for three years. Throughout his career, he has been responsible for building businesses throughout the world, as well as mergers and major restructures. He started his career with Abbott in 1989, working in the infectious diseases area and then held a series of management positions in sales and marketing with Servier, for five years and then for ten years from 1994 to 2005 with Roche Pharmaceuticals, most recently as Country Head for Korea. As Marketing Director in Shanghai, China, he launched eight products during this time, including cardiovascular products. He served as the Chairman of the Board of Admedus Limited from February 9, 2016 to March 14, 2017. He served as Chairman of the Board of Merck Serono Japan. He has been a Director of Admedus Limited since October 10, 2014. Mr. Paterson studied at the Queensland University of Technology where he received his degree in Economics and business studies. He further studied at the University of Southern Queensland and obtained a Master of Business Administration (MBA). He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.

CEO Compensation
  • Wayne's compensation has been consistent with company performance over the past year.
  • Wayne's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Admedus management team in years:

1.1
Average Tenure
  • The average tenure for the Admedus management team is less than 2 years, this suggests a new team.
Management Team

Wayne Paterson

TITLE
CEO, MD & Executive Director
COMPENSATION
A$1M
AGE
51
TENURE
2.1 yrs

Matthew McDonnell

TITLE
Interim Chief Financial Officer
COMPENSATION
A$331K
TENURE
0.4 yrs

David Denis

TITLE
Chief Operating Officer
COMPENSATION
A$777K
TENURE
1.8 yrs

Kiran Bhirangi

TITLE
Chief Medical Officer
COMPENSATION
A$449K
TENURE
0.3 yrs

Steve Denaro

TITLE
Non-Executive Director & Company Secretary
COMPENSATION
A$27K
TENURE
0.5 yrs

Chris Olig

TITLE
Business Development and Portfolio Planning Director
TENURE
2.6 yrs

Danny Zanardo

TITLE
Commercial Director of International

Ian Frazer

TITLE
Executive
Board of Directors Tenure

Average tenure of the Admedus board of directors in years:

0.5
Average Tenure
  • The average tenure for the Admedus board of directors is less than 3 years, this suggests a new board.
Board of Directors

John Seaberg

TITLE
Chairman
COMPENSATION
A$154K
AGE
66
TENURE
2.1 yrs

Wayne Paterson

TITLE
CEO, MD & Executive Director
COMPENSATION
A$1M
AGE
51
TENURE
4.5 yrs

Steve Denaro

TITLE
Non-Executive Director & Company Secretary
COMPENSATION
A$27K
TENURE
0.5 yrs

Wenyi Gu

TITLE
Non-Executive Director
COMPENSATION
A$18K
TENURE
0.5 yrs

Lishan Zhang

TITLE
Non-Executive Director
TENURE
0.3 yrs

Yanheng Wu

TITLE
Non-Executive Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
17. Sep 18 Buy Lishan Zhang Individual 16. May 18 16. May 18 1,666,667 A$0.30 A$500,000
17. Sep 18 Buy Vision Values Holdings Limited Company 22. Aug 18 04. Sep 18 2,839,633 A$0.13 A$321,109
17. Sep 18 Buy Constellation Brands, Inc. Company 22. Aug 18 04. Sep 18 42,594,498 A$0.13 A$4,816,629
17. Sep 18 Buy Constellation Immunotherapy Limited Company 22. Aug 18 04. Sep 18 23,455,371 A$0.13 A$2,652,357
29. Jun 18 Buy Wayne Paterson Individual 28. Jun 18 28. Jun 18 166,667 A$0.30 A$50,000
29. Jun 18 Buy John Seaberg Individual 28. Jun 18 28. Jun 18 166,667 A$0.30 A$50,000
29. Jun 18 Buy Simon H. Buckingham Individual 28. Jun 18 28. Jun 18 333,333 A$0.30 A$100,000
21. May 18 Sell The Metal Group Pty Ltd. Company 02. May 18 17. May 18 -1,204,255 A$0.37 A$-375,600
X
Management checks
We assess Admedus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Admedus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Easy Come, Easy Go: How Admedus (ASX:AHZ) Shareholders Torched 95% Of Their Cash

Admedus Limited (ASX:AHZ) shareholders will doubtless be very grateful to see the share price up 46% in the last month. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Simply Wall St -

What You Must Know About Admedus Limited's (ASX:AHZ) Financial Strength

Investors are always looking for growth in small-cap stocks like Admedus Limited (ASX:AHZ), with a market cap of AU$21m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

What Kind Of Shareholder Owns Most Admedus Limited (ASX:AHZ) Stock?

Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … Admedus is not a large company by global standards.

Simply Wall St -

Does Admedus Limited (ASX:AHZ) Go Up With The Market?

The first type is company-specific risk, which can be diversified away by investing in other companies to reduce exposure to one particular stock. … The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few.

Simply Wall St -

Will You Be Burnt By Admedus Limited's (ASX:AHZ) Cash Burn?

The measure of how fast Admedus goes through its cash reserves over time is called the cash burn rate. … My cash burn analysis suggests that, if Admedus continues to spend its cash reserves at this current high rate, it’ll have to raise capital within the next 4 months, which may be a surprise to some shareholders. … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.

Simply Wall St -

What You Must Know About Admedus Limited's (ASX:AHZ) Major Investors

This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Potential investors in AHZ should also look at another important group of investors: private companies, with a stake of 5.08%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership in AHZ is not at a level that would concern investors.

Simply Wall St -

Does Admedus Limited's (ASX:AHZ) Earnings Growth Make It An Outperformer?

After reading Admedus Limited's (ASX:AHZ) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Admedus, its most recent trailing-twelve-month earnings is -AU$14.55M, which, relative to the prior year's figure, has become less negative.

Simply Wall St -

Have Investors Already Priced In Healthcare Growth For Admedus Limited (ASX:AHZ)?

Not surprisingly, this rate is more than double the growth rate of the Australian stock market as a whole. … In this article, I’ll take you through the sector growth expectations, and also determine whether Admedus is a laggard or leader relative to its healthcare sector peers. … If the stock has been on your watchlist for a while, now may be the time to buy, if you like its ability to deliver growth and are not highly concentrated in the healthcare industry.

Simply Wall St -

All You Need To Know About Admedus Limited's (ASX:AHZ) Risks

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, AHZ appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … AHZ, with its market capitalisation of AU$63.70M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

What's The Cash Runway For Admedus Limited (ASX:AHZ)?

Admedus may need to come to market again, but the question is, when? … Not surprisingly, if Admedus continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves. … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.

Simply Wall St -

Company Info

Description

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company offers CardioCel, a bio-scaffold material to repair congenital heart deformities and other heart defects, as well as to reconstruct dysfunctional heart valves and valve leaflets; and CardioCel 3D that enables physicians access to an arch reconstruction solution with non-antigenic response and calcification resistance. It also provides VascuCel, a collagen scaffold used in cardiac repairs and reconstructions; ambIT infusion pumps for the delivery of medications and pain relief; arcomed infusion systems; and Eldor, a specialized fenestrated catheters for the infusion of local anesthetics into surgical sites for post-operative pain management. In addition, the company offers DOSI-FUSER, a portable elastomeric pump; and DOSI-PAIN, a wound catheter for postoperative continuous infusion. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia.

Details
Name: Admedus Limited
AHZ
Exchange: ASX
Founded:
A$35,396,568
589,942,803
Website: http://www.admedus.com
Address: Admedus Limited
Toowong Tower,
Suite 302,
Toowong,
Queensland, 4066,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX AHZ Ordinary Shares Australian Securities Exchange AU AUD 25. Jun 2011
OTCPK AMEU.F Ordinary Shares Pink Sheets LLC US USD 25. Jun 2011
DB DDF Ordinary Shares Deutsche Boerse AG DE EUR 25. Jun 2011
CHIA AHZ Ordinary Shares Chi-X Australia AU AUD 25. Jun 2011
Number of employees
Current staff
Staff numbers
0
Admedus employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 10:34
End of day share price update: 2019/04/12 00:00
Last estimates confirmation: 2017/08/30
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.